- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Botanix Pharmaceuticals Ltd (BOT)
Botanix Pharmaceuticals Ltd stock price live, this page displays ASX BOT stock exchange data. View the BOT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Botanix Pharmaceuticals Ltd real time stock price chart below.
What Is the Botanix Pharmaceuticals Ltd Stock Price Today?
The Botanix Pharmaceuticals Ltd stock price today is 0.150.
What Is the Stock Symbol for Botanix Pharmaceuticals Ltd?
The stock symbol for Botanix Pharmaceuticals Ltd is ""BOT.""
What Stock Exchange Does Botanix Pharmaceuticals Ltd Trade On?
Botanix Pharmaceuticals Ltd is listed and trades on the Sydney stock exchange.
Is Botanix Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Botanix Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BOT quote. (ISIN: AU000000BOT2)
What Is the Botanix Pharmaceuticals Ltd Stock Price Today?
The Botanix Pharmaceuticals Ltd stock price today is 0.150.
What Is the Stock Symbol for Botanix Pharmaceuticals Ltd?
The stock symbol for Botanix Pharmaceuticals Ltd is ""BOT.""
What Stock Exchange Does Botanix Pharmaceuticals Ltd Trade On?
Botanix Pharmaceuticals Ltd is listed and trades on the Sydney stock exchange.
Is Botanix Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Botanix Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BOT quote. (ISIN: AU000000BOT2)
Sydney
Currency in AUD
0.150
+0.005(+3.45%)
Closed·
Fair Value
An estimate of a Botanix Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.145
0.150
52 wk Range
0.130
0.535
BOT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
BOT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Botanix Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.1450.150
52 wk Range
0.1300.535
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
BOT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Botanix Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
0.900
Upside
+500.00%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Botanix Pharmaceuticals Ltd Company Profile
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in West Perth, Australia.
Botanix Pharmaceuticals Ltd Earnings Call Summary for Q4/2025
- Botanix Pharma's Q4 2025 gross sales surged to $20.4M, up from $4.8M in Q3, driven by successful Softra launch
- Prescriptions increased 324% following Softra launch; operating cash flow improved by $8.4M to $28.4M
- Company aims to expand sales force to 50 reps by FY2026, targets 30-40% gross-to-net yield and cash flow positivity
- FY2025 and FY2026 revenue forecasts set at $3.78M and $42.9M respectively; $64.9M cash and $27M inventory on hand
- Stock gained 9.68% in past week; market cap at $218.85M, trading near 52-week range of $0.09-$0.35
Last Updated: 28/07/2025, 00:40
Read Full TranscriptCompare BOT to Peers and Sector
Metrics to compare | BOT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBOTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.5x | −6.2x | −0.5x | |
PEG Ratio | 0.03 | −0.03 | 0.00 | |
Price/Book | 3.2x | 3.6x | 2.6x | |
Price / LTM Sales | 142.2x | 7.6x | 3.3x | |
Upside (Analyst Target) | 186.7% | 214.3% | 43.5% | |
Fair Value Upside | Unlock | 10.0% | 6.8% | Unlock |
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 0.900
(+500.00% Upside)
Earnings
Latest Release
May 28, 2025
EPS / Forecast
-- / --
Revenue / Forecast
700.00K / --
People Also Watch
FAQ
What Stock Exchange Does Botanix Pharma Trade On?
Botanix Pharma is listed and trades on the Sydney Stock Exchange stock exchange.
What Is the Stock Symbol for Botanix Pharma?
The stock symbol for Botanix Pharma is "BOT."
What Is the Botanix Pharma Market Cap?
As of today, Botanix Pharma market cap is 294.17M.
What Is Botanix Pharma's Earnings Per Share (TTM)?
The Botanix Pharma EPS (TTM) is -0.02.
When Is the Next Botanix Pharma Earnings Date?
Botanix Pharma will release its next earnings report on 27 Aug 2025.
From a Technical Analysis Perspective, Is BOT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Botanix Pharma Stock Split?
Botanix Pharma has split 1 times.
How Many Employees Does Botanix Pharma Have?
Botanix Pharma has 11 employees.
What is the current trading status of Botanix Pharma (BOT)?
As of 09 Aug 2025, Botanix Pharma (BOT) is trading at a price of 0.15, with a previous close of 0.15. The stock has fluctuated within a day range of 0.15 to 0.15, while its 52-week range spans from 0.13 to 0.54.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.